Barclays raised the firm’s price target on MacroGenics (MGNX) to $4 from $3 and keeps an Overweight rating on the shares following the Q4 report. The firm sees the company’s antibody-drug conjugate data in 2026 as a potential source of upside.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGNX: